Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Clinical trial NCT00001337 · COMPLETED

Trial details

NCT number: NCT00001337
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma Burkitt Lymphoma Anaplastic Large-Cell Lymphoma Gray Zone Lymphoma

Start date: 1993-05-08
Primary completion: 2024-05-24
Enrollment: 348

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.